Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 35

1.

Potent and selective N-(4-sulfamoylphenyl)thiourea-based GPR55 agonists.

Yrjölä S, Parkkari T, Navia-Paldanius D, Laitinen T, Kaczor AA, Kokkola T, Adusei-Mensah F, Savinainen JR, Laitinen JT, Poso A, Alexander A, Penman J, Stott L, Anskat M, Irving AJ, Nevalainen TJ.

Eur J Med Chem. 2016 Jan 1;107:119-32. doi: 10.1016/j.ejmech.2015.10.050. Epub 2015 Nov 2.

PMID:
26575458
2.

Revisiting 1,3,4-Oxadiazol-2-ones: Utilization in the Development of ABHD6 Inhibitors.

Patel JZ, van Bruchem J, Laitinen T, Kaczor AA, Navia-Paldanius D, Parkkari T, Savinainen JR, Laitinen JT, Nevalainen TJ.

Bioorg Med Chem. 2015 Oct 1;23(19):6335-45. doi: 10.1016/j.bmc.2015.08.030. Epub 2015 Aug 28.

PMID:
26344596
3.

Increased tonic cannabinoid CB1R activity and brain region-specific desensitization of CB1R Gi/o signaling axis in mice with global genetic knockout of monoacylglycerol lipase.

Navia-Paldanius D, Aaltonen N, Lehtonen M, Savinainen JR, Taschler U, Radner FP, Zimmermann R, Laitinen JT.

Eur J Pharm Sci. 2015 Sep 18;77:180-8. doi: 10.1016/j.ejps.2015.06.005. Epub 2015 Jun 9.

PMID:
26070239
4.

New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor agonists with anticancer and immuno-modulatory activity.

Manera C, Malfitano AM, Parkkari T, Lucchesi V, Carpi S, Fogli S, Bertini S, Laezza C, Ligresti A, Saccomanni G, Savinainen JR, Ciaglia E, Pisanti S, Gazzerro P, Di Marzo V, Nieri P, Macchia M, Bifulco M.

Eur J Med Chem. 2015 Jun 5;97:10-8. doi: 10.1016/j.ejmech.2015.04.034. Epub 2015 Apr 24.

PMID:
25935384
5.

Loratadine analogues as MAGL inhibitors.

Patel JZ, Ahenkorah S, Vaara M, Staszewski M, Adams Y, Laitinen T, Navia-Paldanius D, Parkkari T, Savinainen JR, Walczyński K, Laitinen JT, Nevalainen TJ.

Bioorg Med Chem Lett. 2015 Apr 1;25(7):1436-42. doi: 10.1016/j.bmcl.2015.02.037. Epub 2015 Feb 24.

PMID:
25752982
6.

Optimization of 1,2,5-thiadiazole carbamates as potent and selective ABHD6 inhibitors.

Patel JZ, Nevalainen TJ, Savinainen JR, Adams Y, Laitinen T, Runyon RS, Vaara M, Ahenkorah S, Kaczor AA, Navia-Paldanius D, Gynther M, Aaltonen N, Joharapurkar AA, Jain MR, Haka AS, Maxfield FR, Laitinen JT, Parkkari T.

ChemMedChem. 2015 Feb;10(2):253-65. doi: 10.1002/cmdc.201402453. Epub 2014 Dec 11.

7.

Synthesis, biological activity and molecular modeling of new biphenylic carboxamides as potent and selective CB2 receptor ligands.

Bertini S, Parkkari T, Savinainen JR, Arena C, Saccomanni G, Saguto S, Ligresti A, Allarà M, Bruno A, Marinelli L, Di Marzo V, Novellino E, Manera C, Macchia M.

Eur J Med Chem. 2015 Jan 27;90:526-36. doi: 10.1016/j.ejmech.2014.11.066. Epub 2014 Dec 2.

PMID:
25486424
8.

Biochemical and pharmacological characterization of the human lymphocyte antigen B-associated transcript 5 (BAT5/ABHD16A).

Savinainen JR, Patel JZ, Parkkari T, Navia-Paldanius D, Marjamaa JJ, Laitinen T, Nevalainen T, Laitinen JT.

PLoS One. 2014 Oct 7;9(10):e109869. doi: 10.1371/journal.pone.0109869. eCollection 2014.

9.

Piperazine and piperidine carboxamides and carbamates as inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL).

Korhonen J, Kuusisto A, van Bruchem J, Patel JZ, Laitinen T, Navia-Paldanius D, Laitinen JT, Savinainen JR, Parkkari T, Nevalainen TJ.

Bioorg Med Chem. 2014 Dec 1;22(23):6694-705. doi: 10.1016/j.bmc.2014.09.012. Epub 2014 Sep 16.

PMID:
25282655
10.

Robust hydrolysis of prostaglandin glycerol esters by human monoacylglycerol lipase (MAGL).

Savinainen JR, Kansanen E, Pantsar T, Navia-Paldanius D, Parkkari T, Lehtonen M, Laitinen T, Nevalainen T, Poso A, Levonen AL, Laitinen JT.

Mol Pharmacol. 2014 Nov;86(5):522-35. doi: 10.1124/mol.114.094284. Epub 2014 Aug 19.

11.

Discovery of triterpenoids as reversible inhibitors of α/β-hydrolase domain containing 12 (ABHD12).

Parkkari T, Haavikko R, Laitinen T, Navia-Paldanius D, Rytilahti R, Vaara M, Lehtonen M, Alakurtti S, Yli-Kauhaluoma J, Nevalainen T, Savinainen JR, Laitinen JT.

PLoS One. 2014 May 30;9(5):e98286. doi: 10.1371/journal.pone.0098286. eCollection 2014.

12.

1,2-Dihydro-2-oxopyridine-3-carboxamides: the C-5 substituent is responsible for functionality switch at CB2 cannabinoid receptor.

Lucchesi V, Parkkari T, Savinainen JR, Malfitano AM, Allarà M, Bertini S, Castelli F, Del Carlo S, Laezza C, Ligresti A, Saccomanni G, Bifulco M, Di Marzo V, Macchia M, Manera C.

Eur J Med Chem. 2014 Mar 3;74:524-32. doi: 10.1016/j.ejmech.2013.10.070. Epub 2014 Jan 21.

PMID:
24518874
13.

Mutation of Cys242 of human monoacylglycerol lipase disrupts balanced hydrolysis of 1- and 2-monoacylglycerols and selectively impairs inhibitor potency.

Laitinen T, Navia-Paldanius D, Rytilahti R, Marjamaa JJ, Kařízková J, Parkkari T, Pantsar T, Poso A, Laitinen JT, Savinainen JR.

Mol Pharmacol. 2014 Mar;85(3):510-9. doi: 10.1124/mol.113.090795. Epub 2013 Dec 24.

14.

Chiral 1,3,4-oxadiazol-2-ones as highly selective FAAH inhibitors.

Patel JZ, Parkkari T, Laitinen T, Kaczor AA, Saario SM, Savinainen JR, Navia-Paldanius D, Cipriano M, Leppänen J, Koshevoy IO, Poso A, Fowler CJ, Laitinen JT, Nevalainen T.

J Med Chem. 2013 Nov 14;56(21):8484-96. doi: 10.1021/jm400923s. Epub 2013 Oct 22.

PMID:
24083878
15.

Brain regional cannabinoid CB(1) receptor signalling and alternative enzymatic pathways for 2-arachidonoylglycerol generation in brain sections of diacylglycerol lipase deficient mice.

Aaltonen N, Riera Ribas C, Lehtonen M, Savinainen JR, Laitinen JT.

Eur J Pharm Sci. 2014 Jan 23;51:87-95. doi: 10.1016/j.ejps.2013.08.035. Epub 2013 Sep 3.

PMID:
24012970
16.

Piperazine and piperidine triazole ureas as ultrapotent and highly selective inhibitors of monoacylglycerol lipase.

Aaltonen N, Savinainen JR, Ribas CR, Rönkkö J, Kuusisto A, Korhonen J, Navia-Paldanius D, Häyrinen J, Takabe P, Käsnänen H, Pantsar T, Laitinen T, Lehtonen M, Pasonen-Seppänen S, Poso A, Nevalainen T, Laitinen JT.

Chem Biol. 2013 Mar 21;20(3):379-90. doi: 10.1016/j.chembiol.2013.01.012.

17.

Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12).

Navia-Paldanius D, Savinainen JR, Laitinen JT.

J Lipid Res. 2012 Nov;53(11):2413-24. doi: 10.1194/jlr.M030411. Epub 2012 Sep 11.

18.

The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors.

Savinainen JR, Saario SM, Laitinen JT.

Acta Physiol (Oxf). 2012 Feb;204(2):267-76. doi: 10.1111/j.1748-1716.2011.02280.x. Epub 2011 Apr 22. Review. Erratum in: Acta Physiol (Oxf). 2012 Mar;204(3):460.

19.

Characterization of binding properties of monoglyceride lipase inhibitors by a versatile fluorescence-based technique.

Savinainen JR, Yoshino M, Minkkilä A, Nevalainen T, Laitinen JT.

Anal Biochem. 2010 Apr 1;399(1):132-4. doi: 10.1016/j.ab.2009.12.009. Epub 2009 Dec 11.

PMID:
20005861
20.

Screening of various hormone-sensitive lipase inhibitors as endocannabinoid-hydrolyzing enzyme inhibitors.

Minkkilä A, Savinainen JR, Käsnänen H, Xhaard H, Nevalainen T, Laitinen JT, Poso A, Leppänen J, Saario SM.

ChemMedChem. 2009 Aug;4(8):1253-9. doi: 10.1002/cmdc.200900137. No abstract available.

PMID:
19472270
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk